Revolution Medicines, Inc. - Bathi operasional EBITDA RVMD
Revolution Medicines (RVMD) prospects rely on the success of RAS oncology therapy and a stable roster of R&D experts. The estimated EBITDA visualizes the business's cash returns, where the 0.00 mark characterizes this parameter. Future growth is tied to the approval of lung cancer drugs. Development transparency and the management's scientific approach enable the efficient attraction of capital even during the pre-revenue stage.
Revolution Medicines, Inc. (RVMD) - rincian metrik lan laporan keuangan
- kuotasi saiki lan rata-rata prakiraan nilai:
- rincian nilai pasar emiten:
- indikator nilai buku ekuitas:
- data tingkat utang lan likuiditas finansial:
Rasio Kabeh Utang marang Dana Pribadi Revolution Medicines|RVMD - Utang jangka dawa marang modal|Kewajiban jangka cendhak marang modal Revolution Medicines Inc|RVMD - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku Revolution Medicines|RVMD - Utang jangka dawa perusahaan|Utang jangka cendhak Revolution Medicines|Likuiditas cepet revmed.com
- statistik bathi lan rasio pasar:
RVMD - Penghasilan resik|Proyeksi bathi mangsa ngarep Revolution Medicines|RVMD - Koefisien rega marang bathi|Rasio kapitalisasi marang bathi mangsa ngarep revmed.com|RVMD - Pangali PEG|Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan Revolution Medicines|RVMD - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben siji saham sajrone rolas wulan pungkasan Revolution Medicines|RVMD - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone 12 wulan pungkasan revmed.com|RVMD - Wutah bathi resik saben saham ing taun iki|Dinamika bathi saben saham sing diarepake ing taun ngarep Revolution Medicines
- indikator pendapatan dodolan lan penghasilan bisnis:
Pambiji fundamental perusahaan:Revolution Medicines Corp (RVMD)
Operating profit dynamics allow for an assessment of Revolution Medicines (RVMD) financial resilience to inflationary pressure and borrowing costs. Given the colossal expenditures on developing RAS mutation inhibitors, the EBITDA_Co level on this chart reflects the efficiency of cash flow management before taxes and interest. It is critical for investors to monitor this indicator to promptly detect risks of margin erosion and a potential contraction in market capitalization.
Pesaing Revolution Medicines (RVMD)
ONC - Bathi operasional sadurunge ngurangi amortisasi|HALO: Bathi operasional sadurunge ngurangi amortisasi|AAPG - Bathi operasional EBITDA|CG Oncology (CGON) - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|UroGen Pharma Ltd - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|BCAX (Bicara Bio) - Bathi operasional EBITDA|Bathi sadurunge bunga, pajak, lan amortisasi Personalis Genomics PSNL|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Erasca, Inc. (ERAS)|DCTH (delcath.com) - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi operasional EBITDA YMAB (Y-mAbs Therapeutics, Inc.)|Aura Biosciences Inc (AURA) - Bathi sadurunge bunga, pajak, lan amortisasi|CADL: Bathi operasional sadurunge ngurangi amortisasi|ARAY: Bathi sadurunge mbayar bunga, pajak, lan amortisasi|sellaslifesciences.com (SLS) - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi sadurunge bunga, pajak, lan amortisasi actuatetherapeutics.com (ACTU)|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Citius Oncology|Bathi sadurunge mbayar bunga, pajak, lan amortisasi HURA|Bathi operasional sadurunge ngurangi amortisasi TARA (Protara)|Bathi operasional EBITDA Fate Pharma (FATE)|Aadi Bioscience - Bathi operasional sadurunge ngurangi amortisasi|Bathi perusahaan sadurunge pajak, bunga, lan amortisasi TCRX (TScan Therapeutics Inc)|Champions Oncology Corp - Bathi operasional EBITDA|Pendapatan operasional sadurunge ngurangi amortisasi XBiotech Inc. XBIT|cel-sci.com (CVM) - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi sadurunge bunga, pajak, lan amortisasi OS Therapies, Inc. (OSTX)|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Radiopharm Theranostics|Bathi operasional sadurunge amortisasi ARTV (Artiva)|Bathi operasional sadurunge ngurangi amortisasi ANL (Adlai Nortye Ltd.)|VERU (Veru Inc) - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Tempest Tx TPST|XLO - Bathi operasional sadurunge ngurangi amortisasi|Enochian BioSciences - Bathi operasional EBITDA|Bathi sadurunge bunga, pajak, lan amortisasi Mural Oncology plc|KAPA: Bathi operasional EBITDA|Bathi operasional sadurunge amortisasi OKUR|GDTC (CytoMed Therapeutics Ltd) - Bathi operasional EBITDA|Curis Corp (CRIS) - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi operasional EBITDA APLM|Bathi operasional sadurunge ngurangi amortisasi tharimmune.com THAR|Bathi operasional EBITDA ADVB (Advanced Biomed)|Pendapatan operasional sadurunge ngurangi amortisasi Genprex Inc. (GNPX)|CLDI - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|SBFM (sunshinebiopharma.com) - Bathi operasional sadurunge amortisasi|XBIO: Bathi operasional EBITDA|Bathi sadurunge bunga, pajak, lan amortisasi salariuspharma.com (SLRX)|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Purple Biotech Ltd.|AON (AONC) - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi sadurunge mbayar bunga, pajak, lan amortisasi BeOne Medicines (BGNE)|CKPT (Checkpoint Therapeutics Inc) - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Elevation Oncology - Bathi operasional sadurunge ngurangi amortisasi|iCAD Inc. - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|IKNA - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Notable Labs Ltd (NTBL) - Bathi operasional sadurunge ngurangi amortisasi|VIRX: Bathi operasional EBITDA|Bathi operasional sadurunge amortisasi MOR|NAYA (NAYA Biosciences) - Bathi operasional EBITDA|Bathi operasional sadurunge ngurangi amortisasi ascentage.com (AAPGV)
